Cargando...
GLP-1 based therapeutics: simultaneously combating T2DM and obesity
Glucagon-like peptide-1 (GLP-1) enhances meal-related insulin secretion, which lowers blood glucose excursions. In addition to its incretin action, GLP-1 acts on the GLP-1 receptor (GLP-1R) in the brain to suppress feeding. These combined actions of GLP-1R signaling cause improvements in glycemic co...
Gardado en:
| Publicado en: | Front Neurosci |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Frontiers Media S.A.
2015
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4367528/ https://ncbi.nlm.nih.gov/pubmed/25852463 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fnins.2015.00092 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|